PACIRA BIOSCIENCES, INC.

PCRX ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
Operating Activities
Net Income $7.0M $-99.6M $42.0M $15.9M $42.0M $145.5M $-11.0M $-471.0K
Depreciation & Amortization $91.0M $78.8M $75.6M $91.5M $28.5M $19.9M $19.6M $13.2M
Depreciation $33.7M $21.5M $18.3M $34.2M $15.0M $12.0M $14.0M $13.2M
Amortization $57.3M $57.3M $57.3M $57.3M $13.6M $7.9M $5.7M $0
Stock-Based Compensation $57.5M $51.2M $47.9M $48.1M $42.2M $39.9M $33.7M $31.7M
Net Cash from Operating Activities $152.0M $189.4M $154.6M $145.3M $125.7M $77.0M $70.5M $48.9M
Investing Activities
Capital Expenditures $15.3M $10.6M $15.2M $30.1M $45.9M $37.8M $10.2M $14.5M
Business Acquisitions $16.7M $0 $0 $0 $420.0M $0 $117.7M $0
Net Cash from Investing Activities $99.5M $-83.3M $77.5M $-225.2M $-20.8M $-277.6M $-128.5M $20.6M
Financing Activities
Dividends Paid
Stock Repurchases $148.3M $25.0M $0 $0
Net Cash from Financing Activities $-369.6M $17.4M $-183.0M $-401.5M $380.7M $222.3M $3.7M $9.0M
Net Change in Cash $-118.2M $123.5M $49.2M $-481.4M $485.6M $21.7M $-54.3M $78.4M
Free Cash Flow $136.7M $178.8M $139.5M $115.2M $79.9M $39.2M $60.4M $34.4M
← Newer Page 1 of 3 Older →